Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 468,016 shares at $1.67 ($750K) on 2022-11-01, disclosed to the SEC on 2022-11-03.
Scheduled sale ($750k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.60 | 454,856 | $728K | 97.1% |
| 2 | $1.67 | 13,160 | $22K | 2.9% |
| Total | $1.60 avg | 468,016 | $750K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |